Neuroblastoma Market to Observe Impressive Growth During the Forecast Period (2022-2032), Evaluates DelveInsight | Key Companies - Novartis, AstraZeneca, Bayer, Nova Laboratories Ltd., Jubilant DraxImage Inc., Pfizer, Eli Lilly

DelveInsight's "Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Neuroblastoma, historical and forecasted epidemiology as well as the Neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Neuroblastoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuroblastoma Market Forecast
https://www.delveinsight.com/report-store/neuroblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Neuroblastoma Market Report:
• The Neuroblastoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In December 2021, Phase II data of hu14.18K322A was published at ASCO journal, data showed improved outcome in children with newly diagnosed high-risk neuroblastoma treated with chemo immunotherapy
• In September 2021, Y-mAbs Therapeutics presented data from phase II trial of Naxitamab for the treatment of refractory/relapsed high-risk neuroblastoma. The anti-GD2antibody naxitamab showed a high response rate of 58% with a manageable toxicity profile in patients with relapsed high-riskThe key driver for the surge in market size neuroblastoma
• Key Neuroblastoma Companies: Clarity Pharmaceuticals, Novartis, AstraZeneca, Bayer, Nova Laboratories Ltd., Jubilant DraxImage Inc., Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, Autolus Therapeutics, Innervate Radiopharma, Molecular Insight Pharma, Laboratorio Elea Phoenix S.A., GE Healthcare, Genentech, Inc., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, NanoPharmaceuticals, Aptorum Group, and others
• Key Neuroblastoma Therapies: 67Cu-SARTATE, Topotecan, Gefitinib, Liquid 13-Cis Retinoic Acid, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG, 18F-MFBG, UltratraceTM Iobenguane, Racotumomab, 123I-mIBG, Bevacizumab, Irinotecan and Temozolomide, 131I-MIBG, Nifurtimox, and others
• The Neuroblastoma epidemiology based on gender analyzed that Neuroblastoma affects males slightly more than females
• The Neuroblastoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuroblastoma pipeline products will significantly revolutionize the Neuroblastoma market dynamics.

Neuroblastoma Overview
Neuroblastoma is an embryonal malignancy of the sympathetic nervous system arising from neuroblasts (pluripotent sympathetic cells). It is derived from two words i.e. "neuro" means nerves and "blastoma" refers to the tumor affecting the immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.

Get a Free sample for the Neuroblastoma Market Report
https://www.delveinsight.com/sample-request/neuroblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuroblastoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neuroblastoma Epidemiology Segmentation:
The Neuroblastoma market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Neuroblastoma
• Prevalent Cases of Neuroblastoma by severity
• Gender-specific Prevalence of Neuroblastoma
• Diagnosed Cases of Episodic and Chronic Neuroblastoma

Download the report to understand which factors are driving Neuroblastoma epidemiology trends @ Neuroblastoma Epidemiology Forecast
https://www.delveinsight.com/sample-request/neuroblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuroblastoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuroblastoma market or expected to get launched during the study period. The analysis covers Neuroblastoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Neuroblastoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neuroblastoma Therapies and Key Companies
• 67Cu-SARTATE: Clarity Pharmaceuticals
• Topotecan: Novartis
• Gefitinib: AstraZeneca
• Liquid 13-Cis Retinoic Acid: Nova Laboratories Limited
• Omburtamab: Y-mabs therapeutics
• LY 3295668: Eli Lilly
• Racotumomab: LaboratorioElea Phoenix
• Eflornithine: K C Pharmaceuticals
• AUTO6NG: AutolusTherapeutics
• 18F-MFBG: Innervate Radiopharmaceuticals
• UltratraceTM Iobenguane: Molecular Insight Pharmaceuticals
• Racotumomab: Laboratorio Elea Phoenix S.A.
• 123I-mIBG: GE Healthcare
• Bevacizumab, Irinotecan and Temozolomide: Genentech, Inc.
• 131I-MIBG: Jubilant DraxImage Inc.
• Nifurtimox: Bayer

Discover more about therapies set to grab major Neuroblastoma market share @ Neuroblastoma Treatment Market
https://www.delveinsight.com/sample-request/neuroblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Neuroblastoma Market Strengths
• The neuroblast may be caused due to the immature cell growth or mutation in the gene responsible for controlling cell proliferation. The increasing cases of childhood cancer, rising research on Neuroblastoma treatment and increasing spending on cancer treatment is expected to drive market growth over the forecast period

Neuroblastoma Market Opportunities
• Understanding of neuroblastoma biology deepens, our approaches to therapy for this disease continue to evolve. Improved risk stratification and the use of predictive biomarkers will aid in treatment selection for patients with neuroblastoma, and it is expected that future treatments will be associated with greater efficacy and less toxicity

Scope of the Neuroblastoma Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Neuroblastoma Companies: Clarity Pharmaceuticals, Novartis, AstraZeneca, Bayer, Nova Laboratories Ltd., Jubilant DraxImage Inc., Y-mabs therapeutics, Eli Lilly, LaboratorioElea Phoenix, K C Pharmaceuticals, Autolus Therapeutics, Innervate Radiopharma, Molecular Insight Pharma, Laboratorio Elea Phoenix S.A., GE Healthcare, Genentech, Inc., PersonGen BioTherapeutics (Suzhou) Co., Ltd., Advanced Accelerator Applications, Curis, Inc., Pfizer, Valent Technologies, LLC, UGISense AG, Y-mAbs Therapeutics, Ascentage Pharma, Kuur Therapeutics, Cell Medica, NanoPharmaceuticals, Aptorum Group, and others
• Key Neuroblastoma Therapies: 67Cu-SARTATE, Topotecan, Gefitinib, Liquid 13-Cis Retinoic Acid, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG, 18F-MFBG, UltratraceTM Iobenguane, Racotumomab, 123I-mIBG, Bevacizumab, Irinotecan and Temozolomide, 131I-MIBG, Nifurtimox, and others
• Neuroblastoma Therapeutic Assessment: Neuroblastoma current marketed and Neuroblastoma emerging therapies
• Neuroblastoma Market Dynamics: Neuroblastoma market drivers and Neuroblastoma market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Neuroblastoma Unmet Needs, KOL's views, Analyst's views, Neuroblastoma Market Access and Reimbursement

To know more about Neuroblastoma companies working in the treatment market, visit @ Neuroblastoma Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/neuroblastoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Neuroblastoma Market Report Introduction
2. Executive Summary for Neuroblastoma
3. SWOT analysis of Neuroblastoma
4. Neuroblastoma Patient Share (%) Overview at a Glance
5. Neuroblastoma Market Overview at a Glance
6. Neuroblastoma Disease Background and Overview
7. Neuroblastoma Epidemiology and Patient Population
8. Country-Specific Patient Population of Neuroblastoma
9. Neuroblastoma Current Treatment and Medical Practices
10. Neuroblastoma Unmet Needs
11. Neuroblastoma Emerging Therapies
12. Neuroblastoma Market Outlook
13. Country-Wise Neuroblastoma Market Analysis (2019-2032)
14. Neuroblastoma Market Access and Reimbursement of Therapies
15. Neuroblastoma Market Drivers
16. Neuroblastoma Market Barriers
17. Neuroblastoma Appendix
18. Neuroblastoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Neuroblastoma Pipeline
https://www.delveinsight.com/report-store/neuroblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Neuroblastoma Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Neuroblastoma market. A detailed picture of the Neuroblastoma pipeline landscape is provided, which includes the disease overview and Neuroblastoma treatment guidelines.
Neuroblastoma Epidemiology
https://www.delveinsight.com/report-store/neuroblastoma-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Neuroblastoma Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Neuroblastoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:

• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.